---
stable_id: R-HSA-9725855
display_name: NR3C2 binds NR3C2 antagonists
species: Homo sapiens
summary: The mineralocorticoid receptor (Nuclear receptor subfamily 3 group C member
  2, NR3C2) is a receptor with equal affinity for both mineralocorticoids (MC) such
  as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. NR3C2
  is expressed in many tissues such as kidney, heart, the CNS and sweat glands. Its
  activation leads to the expression of proteins regulating ionic and water transport
  resulting in the reabsorption of sodium. Consequently, there is an increase in extracellular
  volume, an increase in blood pressure, and increased excretion of potassium to maintain
  normal salt concentrations.<br><br>Synthetic NR3C2 antagonists competitively inhibit
  NR3C2 (Kagawa et al. 1957, Pollow et al. 1992, Rupprecht et al. 1993) in the kidney
  distal convoluted tubule to promote sodium and water excretion and potassium retention.
  These diuretic drugs are typically indicated for congestive heart failure, hypertension
  and chronic kidney disease. Synthetic antagonists of NR3C2 include the steroidal
  compounds spironolactone, eplerenone, and drospirenone. Nimodipine, a calcium channel
  blocker, can also act as an NR3C2 antagonist (Dietz et al. 2008, Luther 2014).<br><br>The
  broad clinical use of steroidal mineralocorticoid receptor antagonists is limited
  by the potential risk of inducing hyperkalemia. Novel, non-steroidal NR3C2 antagonists
  demonstrate an improved therapeutic index for hyperkalemic risk compared to their
  steroidal counterparts in preclinical models (reviews Kolkhof et al. 2015, Kolkhof
  & B채rfacker 2017, Sueta et al. 2020). Compounds undergoing clinical trials include
  apararenone (no trial data), esaxerenone (Arai et al. 2015), and finerenone (B채rfacker
  et al. 2012, Amazit et al. 2015).
---

# NR3C2 binds NR3C2 antagonists
**Reactome ID:** [R-HSA-9725855](https://reactome.org/content/detail/R-HSA-9725855)
**Species:** Homo sapiens

## Summary

The mineralocorticoid receptor (Nuclear receptor subfamily 3 group C member 2, NR3C2) is a receptor with equal affinity for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. NR3C2 is expressed in many tissues such as kidney, heart, the CNS and sweat glands. Its activation leads to the expression of proteins regulating ionic and water transport resulting in the reabsorption of sodium. Consequently, there is an increase in extracellular volume, an increase in blood pressure, and increased excretion of potassium to maintain normal salt concentrations.<br><br>Synthetic NR3C2 antagonists competitively inhibit NR3C2 (Kagawa et al. 1957, Pollow et al. 1992, Rupprecht et al. 1993) in the kidney distal convoluted tubule to promote sodium and water excretion and potassium retention. These diuretic drugs are typically indicated for congestive heart failure, hypertension and chronic kidney disease. Synthetic antagonists of NR3C2 include the steroidal compounds spironolactone, eplerenone, and drospirenone. Nimodipine, a calcium channel blocker, can also act as an NR3C2 antagonist (Dietz et al. 2008, Luther 2014).<br><br>The broad clinical use of steroidal mineralocorticoid receptor antagonists is limited by the potential risk of inducing hyperkalemia. Novel, non-steroidal NR3C2 antagonists demonstrate an improved therapeutic index for hyperkalemic risk compared to their steroidal counterparts in preclinical models (reviews Kolkhof et al. 2015, Kolkhof & B채rfacker 2017, Sueta et al. 2020). Compounds undergoing clinical trials include apararenone (no trial data), esaxerenone (Arai et al. 2015), and finerenone (B채rfacker et al. 2012, Amazit et al. 2015).
